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DObjective: Latest generation biologic aortic valve prostheses were designed to improve hemodynamic perfor-
mance. We sought to determine whether there are clinically important early differences among these devices.
Methods: Three hundred adults with severe aortic valve stenosis undergoing aortic valve replacement were
randomized to receive the Edwards Magna, Sorin Mitroflow, or St. Jude Epic bioprostheses (n ¼ 100,
n ¼ 101, n ¼ 99, respectively). Early hemodynamic performance was studied by echocardiography.
Results: Mean patient age was 76  8 years and there were 203 men (68%). There were no significant differ-
ences in baseline characteristics among implant groups. Early mortality was 1.7%, and there were no differences
in early adverse events. Postoperative echocardiography showed small but statistically significant differences
overall between the Magna, Mitroflow, and Epic valves in mean gradient (14.2 mm Hg, 16.3 mm Hg, 16.5
mm Hg, respectively; P ¼ .011), aortic valve area (2.05 cm2, 1.88 cm2, 1.86 cm2, respectively; P ¼ .012),
and indexed aortic valve area (1.05 cm2/m2, 0.97 cm2/m2, 0.95 cm2/m2, respectively; P ¼ .012). Prosthetic per-
formance was similar among all with a small (21 mm) aortic annulus. Patients who received the Magna device
with a 23-mm annulus had slightly greater indexed aortic valve area; those with>23 mm had a slightly lower
transprosthetic gradient. Analogous trends were found when data were stratified by either commercial implant
size or echocardiography-determined aortic annulus size. Severe patient–prosthesis mismatch was infrequent
overall and was similarly low among devices (P value not significant).
Conclusions: This prospective, randomized comparison reveals that there are small but consistent early post-
operative hemodynamic differences among current third-generation porcine and pericardial aortic valve pros-
theses. The 3 valves studied performed equally well in patients with a small (21 mm) aortic annulus. The
Magna valve had a slightly lower mean gradient in those with larger annular size (>23 mm). Longitudinal
follow-up of these randomized cohorts is essential to determine late clinical implications of these early postop-
erative findings. (J Thorac Cardiovasc Surg 2012;144:1387-98)Palliation of severe calcific aortic valve stenosis (AS) via
prosthetic valve replacement may impose additional disease
burden in the form of excess residual transprosthetic gradi-
ent in addition to either structural valve deterioration with
biologic devices or mandatory anticoagulation for mechan-
ical valve substitutes. Commercial heart valve companies
have sought to promote the utilization of third-generation
bioprosthetic valves by promising diminished residual gra-
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The Journal of Thoracic and Carcomplicate the comparison of early hemodynamic
performance among devices, including heterogeneity of
commercial valve sizers, differing prosthetic leaflet tissue
types (bovine vs porcine),9 varied leaflet preservation/anti-
calcification treatment, and the disparate study designs
within which devices are compared.
Despite commercial claims of differing hemodynamic
performance and clinical outcomes, third-generation bio-
logic heart valve prostheses have seldom been compared
in prospective, randomized trials. We therefore sought to
study the early clinical and hemodynamic differences be-
tween 3 commonly used biologic aortic valve substi-
tutes—the St. Jude Epic porcine (St. Jude Medical,
Minneapolis, Minn), the Sorin Mitroflow bovine pericardial
valve (Sorin Group, Saluggia, Italy), or the Edwards Magna
(Edwards LifeSciences, Irvine, Calif) aortic valves—
following randomized assignment to 300 patients with
severe AS undergoing aortic valve replacement (AVR).
METHODS
The study was approved by theMayo Clinic Institutional Review Board.diovascular Surgery c Volume 144, Number 6 1387
Abbreviations and Acronyms
AS ¼ aortic valve stenosis
AVA ¼ aortic valve area
AVAi ¼ indexed AVA
AVR ¼ aortic valve replacement
BSA ¼ body surface area
EF ¼ ejection fraction
LV ¼ left ventricular
LVEF ¼ left ventricular ejection fraction
LVOT ¼ left ventricular outflow tract
PPM ¼ patient-prosthesis mismatch




From August 13, 2009, to November 9, 2011, 300 consecutive patients
with severe AS who were referred for biologic AVR were considered for
enrollment. Included were those with a history of healed aortic valve endo-
carditis and patients undergoing concomitant procedures such as coronary
artery bypass grafting or valve repair. Patients with the following character-
istics were not included in the study:<18 years of age, emergency surgery,
preexisting prosthetic heart valve in any location, previous aortic valve pro-
cedure or aortic root replacement, concomitant replacement of valves other
than the aortic, active endocarditis, or severe aortic insufficiency (AV re-
gurgitant volume>60 mL/beat). All patients provided informed consent
and expressed a willingness to follow the requirements of the protocol.
Aortic Valve Replacement
Randomization numbers were generated by the statistician using the
SAS program (SAS9.2; SAS Institute, Inc, Cary, NC), printed on cards,
and placed inside sealed envelopes. Patients underwent standard cardio-
pulmonary bypass and cold-blood cardioplegic arrest. After aortotomy,
excision of the native aortic valve cusps, and debridement of the aortic
annulus, the native aortic annulus was measured using a calibrated uni-
versal sizer (19, 21, 23, 25, 27, and 29 mm). A decision was then
made by the operative surgeon whether to enlarge the aortic annulus at
that point in the operation prior to randomization. If the annulus was
patch enlarged, the neo-annular size was remeasured with the universal
sizer. The randomization envelope was then opened and the surgeon
was instructed regarding the valve type to be implanted: the Edwards Ma-
gna, the St. Jude Epic, or the Sorin Mitroflow. Next, the annulus was
measured using proprietary aortic sizers supplied by the valve manufac-
turers according to their recommended techniques. Surgeons assessed the
geospatial relationship of the propriety replica aortic valve sizer within
the aortic root and made a decision regarding whether a smaller prosthe-
sis would need to be placed (ie, downsized) to facilitate implantation. Ev-
ery effort was made by the surgeon to implant the largest possible aortic
valve prosthesis. Aortic valve devices were implanted using noneverting
pledgeted stitches. Patch closure of the aortic root was performed as in-
dicated by the technical inability to close the aortotomy around strut posts
of the implanted device.
The St. Jude Epic Supra porcine bioprosthesis is a triple-composite
bioprosthetic heart valve manufactured from select porcine aortic valve
cusps. The cusps are matched for leaflet coaptation. After fixation, the tis-
sue is mounted on a polyester-covered flexible copolymer stent and was
used in sizes 19 through 27 for the study. The Edwards Magna tissue valve
is comprised of glutaraldehyde-fixed bovine pericardium mounted on
a 3-pronged polyester Elgiloy stent and is available in sizes 19 through
27. The Sorin Mitroflow stented pericardial bioprosthesis is constructed
from glutaraldehyde-fixed bovine pericardium sutured onto a polyester
cloth-covered, flexible acetyl homopolymer stent. The pericardial tissue1388 The Journal of Thoracic and Cardiovascular Surthickness is matched to the stent diameter and the valve is available in sizes
19 through 27.
Echocardiography
All patients underwent comprehensive 2-dimensional and Doppler
transthoracic echocardiographic evaluation with state-of-the-art technol-
ogy preoperatively and prior to hospital dismissal. Multiplane transesopha-
geal echocardiography was used intraoperatively, and intraoperative data
were reported whenever additional preoperative information was not avail-
able using transthoracic data. Left ventricular ejection fraction (LVEF) was
assessed with 2-dimensional echocardiography by measuring the left ven-
tricular (LV) short axis using a modification of the method of Quinones and
colleagues10 or visual estimation.11 Pulsed and continuous-wave Doppler
measurements were performed according to best practice,12 with a mea-
surement average of 3 beats in sinus rhythm and 5 to 10 beats in atrial fi-
brillation. With appropriate gain and processing adjustments, the left
ventricular outflow tract (LVOT) diameter was measured in the parasternal
long axis within a midsystolic zoomed freeze frame, inner edge to inner
edge from where the anterior cusp meets the ventricular anteroseptum to
the point where the posterior cuspmeets the anterior mitral leaflet for native
aortic valves, and from the outer edge of the anterior sewing ring to the
outer edge of the posterior sewing ring for prosthetic aortic valves. The
LVOT time–velocity integral was obtained after proper cursor alignment
to the aortic flow, in the apical 3-chamber view, with a sample volume
placed above the color-flow prestenotic acceleration aliasing zone (0.5-1
cm above the aortic annulus) to record a laminar Doppler envelope without
spectral dispersion.13 The transvalvular time–velocity integral, peak trans-
valvular velocity, and mean transvalvular gradient were determined by
a systematic search of the highest values in all possible windows (apical,
subcostal, supraclavicular, suprasternal, and right parasternal) with the
nonimaging continuous-wave probe. The aortic mean gradient, peak
velocity, and aortic valve time–velocity integral were calculated
automatically by echocardiographic software. Aortic valve area
(AVA) was calculated automatically by the continuity equation as
AVA ¼ LVOTd2 3 0.785 3 LVOT – TVI/AV – TVI, where TVI is trans-
valvular time-velocity integral and AV is aortic valve; and AVA indexed
(AVAi) as AVAi ¼ AVA/BSA, where BSA is body surface area. Valvular
regurgitation was assessed according to state-of-the-art guidelines.14
Stroke work loss was expressed as a percentage and was obtained using
the equation 100 3 (DP/DP 3 SPB), where SPB is systolic blood pres-
sure.15 Patient–prosthesis mismatch (PPM)16 was calculated according to
Rahimtoola17-19 as AVA/BSA < 0.6 cm2/m2. One cardiologist
specializing in echocardiographic imaging (H.I.M.) supervised the
uniform collection and reporting of echocardiographic data in this study.Statistical Methods
The sample size calculations were based on 2-sample t test. The follow-
ing formula was used to determine the sample size for detecting the differ-
ence of d ¼ mcmi between any 2 of the 3 groups, where N is the sample
size for each group and s is the common standard deviation:




Based on an overall significance level of 0.05, with Bonferroni adjust-
ment for multiple comparisons, a power of 80%, and a common standard
deviation of 5, we estimated that we would require approximately 68 pa-
tients per group to detect a difference of 2.8 in mean predischarge gradient
between any 2 of the 3 groups. To take into consideration possible dropouts,
100 patients were enrolled in each group.
Descriptive statistics for categorical variables are reported as fre-
quency and percentage whereas continuous variables are reported as
mean (standard deviation) or median (range) as appropriate. Categori-
cal variables were compared between groups using the c2 test or Fishergery c December 2012
TABLE 1. Baseline characteristics
Characteristic Epic (n ¼ 99) Magna (n ¼ 100) Mitroflow (n ¼ 101) P value
Age 75.93  8.12 (77.00) 75.50  7.39 (76.50) 75.59  8.68 (77.00) .874
Body mass index 30.18  5.72 (29.45) 30.07  6.21 (29.95) 30.79  6.28 (30.30) .729
Coronary artery disease>50% in 1 vessel 35 (35) 33 (33) 39 (39) .706
Cardiac index, L/min/m2 3.16  0.63 (3.03) 3.26  0.60 (3.27) 3.18  0.68 (3.05) .471
Congestive heart failure 6 (6) 6 (6) 6 (6) .999
Chronic kidney failure 4 (4) 4 (4) 1 (1) .348
Chronic obstructive pulmonary disease 7 (7) 16 (16) 9 (9) .098
Diabetes 21 (21) 20 (20) 26 (26) .588
Etiology of aortic valve disease
Congenital bicuspid 15 (15) 22 (22) 19 (19) .463
Degenerative senile calcific 79 (80) 76 (76) 77 (76) .774
Rheumatic/other 5 (5) 2 (2) 5 (5) .472
Male 73 (74) 64 (64) 66 (65) .282
Myocardial infarction 11 (11) 10 (10) 8 (8) .740
NYHA class 3-4 43 (48) 45 (48) 35 (39) .375
Prior cardiovascular surgery 5 (5) 7 (7) 5 (5) .779
Renal failure (dialysis dependent) 2 (2) 1 (1) 0 (0) .357
Rhythm
Atrial fibrillation/flutter 9 (9) 6 (6) 4 (4) .325
Normal sinus 84 (85) 86 (86) 89 (88) .792
Other 6 (6) 8 (8) 8 (8) .838
Smoking 1 (1) 2 (2) 2 (2) .823
Systemic hypertension 72 (72) 65 (65) 71 (71) .481
Transient ischemic attack/cerebrovascular
accident (%)
7 (7) 12 (12) 4 (4) .097
Echocardiogram
Aorta size (n ¼ 69) 36.97  4.34 (36.00) (n ¼ 61) 36.54  4.15 (36.00) (n ¼ 76) 35.75  3.63 (35.00) .156
Aortic valve area, cm2 0.91  0.21 (0.91) 0.88  0.20 (0.88) 0.87  0.19 (0.87) .404
Aortic valve area index, cm2/m2 0.46  0.11 (0.44) 0.45  0.10 (0.44) 0.45  0.09 (0.44) .800
Ejection fraction (%) 60.02  11.12 (63.00) 60.51  11.20 (63.00) 61.75  11.31 (65.00) .233
Left ventricular outflow tract, cm 2.29  0.20 (2.30) 2.26  0.19 (2.20) 2.25  0.19 (2.20) .334
Mean gradient, mm Hg 48.50  14.14 (45.00) 50.85  14.44 (50.00) 49.13  14.67 (46.00) .386
Peak velocity, m/s 4.44  0.64 (4.40) 4.47  0.69 (4.50) 4.44  0.69 (4.40) .834
Continuous variables are summarized as mean  standard deviation (median) and categorical variables are summarized as n (percentage). NYHA, New York Heart Association.
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sis of variance or the Kruskal-Wallis test when appropriate. All statis-
tical tests were 2-sided, with the alpha level set at .05 for statistical
significance.
Statement of Responsibility
The authors had full access to the data and take responsibility for its
integrity. All authors have read and agree to the manuscript as written.
RESULTS
Preoperative
Baseline characteristics for all 3 groups are reported in
Table 1. Other than heart rhythm, there were no significant
differences in either clinical or echocardiographic variables
among implant groups prior to AVR. Just less than half of
the patients had class III to IV symptoms preoperatively,
and 77% (n¼ 232) underwent AVR to relieve severe senile
calcific AS. Mean preoperative EF was 60.8%, average
mean transaortic gradient was 49.5 mm Hg, and mean
AVA was 0.88 cm2. Prior cardiac surgery had beenThe Journal of Thoracic and Carperformed in 6% of patients (n¼ 17), with similar frequen-
cies among groups (P ¼ .779). The Epic valve was im-
planted in 99 patients, the Magna in 100 patients, and the
Mitroflow in 101 patients.
Operative
Concomitant procedures were performed in 52% of
patients (n ¼ 156) and include, broadly, aortic annular
enlargement (n ¼ 13, 4%), septal myectomy (n ¼ 17,
6%), coronary bypass grafting (n ¼ 111, 37%), mitral
valve repair (n ¼ 8, 2.7%), tricuspid valve repair
(n ¼ 4, 1%), ascending aortic replacement (n ¼ 10,
3%), aortic root replacement (n ¼ 2, 1%), and ablation
for atrial fibrillation (n ¼ 13, 4%). There were no other
important operative differences among groups (Table 2).
Median crossclamp time was 45 minutes for those having
isolated AVR and was 57 minutes overall, with no signif-
icant differences among valves (P ¼ .39 and P ¼ .70, re-
spectively). Early adverse events were infrequent, withdiovascular Surgery c Volume 144, Number 6 1389
TABLE 2. Perioperative outcomes
Outcome Epic (n ¼ 99) Magna (n ¼ 100) Mitroflow (n ¼ 101) P value
Bypass time, min 86.64  71.70 (70.00) 84.20  42.51 (75.50) 82.33  43.12 (71.00) .803
Isolated aortic valve replacement
bypass time, min
(n ¼ 49) 57.78  27.98 (53.00) (n ¼ 46) 57.48  21.59 (52.50) (n ¼ 49) 62.45  22.85 (60.00) .306
Crossclamp time, min 63.03  30.65 (57.00) 66.13  30.95 (60.00) 64.74  30.88 (52.00) .704
Isolated aortic valve replacement
crossclamp time, min
(n ¼ 49) 46.45  17.90 (43.00) (n ¼ 46) 54.17  16.31 (42.00) (n ¼ 49) 50.84  17.54 (48.00) .189
Concomitant procedure 50 (51) 54 (54) 52 (51) .878
Aortic annulus enlargement 5 (5) 4 (4) 4 (4) .912
Patch aortic root closure (without
annular enlargement)
7 (7) 11 (11) 8 (8) .584
Septal myectomy 4 (4) 7 (7) 6 (6) .658
Early mortality* (%) 2 (2) 1 (1) 2 (2) .816
Hospital stay, day 6.47  3.50 (5.00) 6.37  3.76 (5.50) 6.54  3.80 (6.00) .873
Reoperation for bleeding 1 (1) 3 (3) 0 (0) .169
Transient ischemic attack/
cerebrovascular accident (%)
1 (1) 0 (0) 3 (3) .175
Continuous variables are summarized as mean  standard deviation (median) and categorical variables are summarized as n (percentage). *Death in hospital or within 30 days.
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patients (1.3%) requiring reoperation for bleeding. Five
patients died (1.7%) in the hospital or within 30 days
of surgery.
Postoperative
Predismissal echocardiograms were performed at a me-
dian of 4 days after surgery (Table 3). Overall EF was
similar among groups (Table 3,P¼ .070), as was cardiac in-
dex (P ¼ .416). Overall mean transprosthetic gradient was
slightly lower forMagna than for Epic (P¼ .023) andMitro-
flow (P ¼ .040); however, there was no difference between
Epic and Mitroflow (P¼ .972). Peak velocity was lower for
Magna than for Epic (P ¼ .005) and Mitroflow (P ¼ .039);
however, there was no difference between Epic and Mitro-
flow (P ¼ .748). AVA was slightly higher for Magna than
for Epic (P ¼ .023) and Mitroflow (P ¼ .040); however,
there was no difference between Epic and Mitroflow
(P ¼ .972). AVAi was slightly higher for Magna than Epic
(P ¼ .032), but Magna and Mitroflow were similar
(P ¼ .097) as were Epic and Mitroflow (P ¼ .868). Stroke
work loss was lowest for the Magna compared with that of
Epic (P ¼ .008), and Mitroflow (P ¼ .009); however, there
was no difference between Epic and Mitroflow (P ¼ .997).TABLE 3. Dismissal echocardiogram
Variable Epic (n ¼ 99)
Mean gradient, mm Hg 16.51  6.42 (16.00) 1
Aortic valve area, cm2 1.86  0.48 (1.77)
Aortic valve area index, cm2/m2 0.95  0.25 (0.90)
Cardiac index, L/min/m2 3.34  0.65 (3.33)
Ejection fraction,% 57.42  11.89 (60.00) 6
Peak velocity, m/s 2.72  0.48 (2.70)
Stroke work loss,% 12.05  4.10 (11.42) 1
Echocardiogram variables are summarized as mean  standard deviation (median).
1390 The Journal of Thoracic and Cardiovascular SurWhen patients were divided into 3 similar-size groups for
comparison (Figure 1 and Appendix 1), the following co-
horts of commercially labeled valve size were obtained:
nos. 19 and 21 (n ¼ 100), no. 23 (n ¼ 94), and nos. 25
and 27 (n ¼ 106). There were no significant differences in
mean gradient, AVA, or AVAi among commercial valve
types in those receiving the smallest device sizes (nos. 19
and 21). Hemodynamic differences emerged among those
receiving a no. 23 valve when considering mean gradient
(P ¼ .032), AVA (P ¼ .025), and AVAi (P ¼ .028). Among
patients receiving a no. 25 or no. 27 Magna valve, the mean
gradient was slightly lower (P ¼ .009) and the AVA was
slightly higher (P ¼ .019).
When the stratification was based on actual annulus
size as ascertained by calibrated universal sizer measure-
ment at surgery (Figure 2 and Appendix 2), fewer
differences among devices were identified. Most hemo-
dynamic parameters were not significantly different
among valve types aside from 2 categories: patients
with an annulus size of 23 mm who received the Magna
device had a slightly larger AVAi, and those>23 mm had
a slightly lower gradient. No other significant differences
emerged among devices when stratified by actual annu-
lus size. Echocardiographically measured aorticMagna (n ¼ 100) Mitroflow (n ¼ 101) P value
4.23  5.48 (14.00) 16.31  6.09 (16.00) .011
2.05  0.54 (1.98) 1.88  0.52 (1.82) .012
1.05  0.25 (1.00) 0.97  0.27 (0.96) .012
3.50  0.73 (3.36) 3.44  0.70 (3.41) .416
0.46  11.63 (64.00) 59.98  10.66 (61.00) .070
2.49  0.45 (2.50) 2.66  0.50 (2.70) .005
0.30  3.62 (9.92) 12.01  4.27 (11.62) .004
gery c December 2012
FIGURE 1. Early aortic valve prosthesis hemodynamics stratified by
labeled valve size: nos. 19 and 21, no. 23, and nos. 25 and 27. A, Mean gra-
dient was significantly lower in the Magna group for mid- (no. 23) to large-
size (nos. 25 and 27) devices. B, Mean aortic valve area ( 95% confidence
internal whiskers) was significantly higher in the Magna group for mid-
(no. 23) to large-size (nos. 25 and 27) devices. C, Mean indexed aortic
valve area was significantly higher in the Magna group for only mid-size
(no. 23) devices. Mean andmedian are represented by the squares and lines
inside the box. Top and bottom box borders cover the middle 50% of the
data. Star indicates statistically significant comparison.
FIGURE 2. Early aortic valve prosthesis hemodynamics stratified by ac-
tual annular size (universal sizer) measured directly at surgery:<23 mm,
23mm, and>23 mm. A,Mean gradient was only lower in theMagna group
in patients with a large aortic annulus (>23 mm). B, Mean aortic valve area
was similar among all valves when stratified by each actual annulus size.
C, Mean indexed aortic valve area was only higher in the Magna group
for patients with a midsize (23-mm) aortic annulus. Mean and median
are represented by the squares and lines inside the box. Top and bottom
box borders cover the middle 50% of the data. Star indicates statistically
significant comparison.
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FIGURE 3. Incidence of severe patient–prosthesis mismatch (PPM; cal-
culated as indexed aortic valve area<0.6cm2/m2). The frequency of severe
PPM was statistically similar among groups when stratified by either la-
beled valve size (A) or actual annular size (universal sizer; B).











Epic 19 19 25 14
Magna 18 19 24 14
Mitroflow 15.4 18.6 21 11
No. 21
Epic 21 21 28 15
Magna 20 21 26 15
Mitroflow 17.3 20.7 23 13
No. 23
Epic 23 23 29 16
Magna 22 23 28 16
Mitroflow 19 22.7 26 14
No. 25
Epic 25 25 31 17
Magna 24 25 30 17
Mitroflow 21 25.1 29 15
No. 27
Epic 27 27 33 19
Magna 26 27 32 18
Mitroflow 22.9 27.3 31 16
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trends (Appendix 3).
The frequency of severe PPMwas next calculated among
devices based on labeled valve size (Figure 3, A) and actual
annulus size (Figure 3, B). Although patients who received
the Magna device had a slightly higher frequency of severe
PPM in small-labeled valve size (3/29, 10%; P¼ .765) and
small annulus size<23 mm (3/23, 14%; P ¼ .648), the dif-
ferences were not significant. The incidence of prosthetic
regurgitation grademild was very low and similar among
valve groups: Epic, 1% (n ¼ 1); Magna, 2% (n ¼ 2); and
Mitroflow, 4% (n ¼ 4; P ¼ .37).
To understand more completely the relationship be-
tween the aortic annulus size and implanted valve size,
Pearson correlation coefficients were calculated. Prosthe-
sis dimensions reported by the 3 valve companies are
shown in Table 4. Among all valve sizes, the actual annu-
lus size and implant size correlated slightly better in the
Epic (P ¼ .049) and Mitroflow (P ¼ .049) groups versus
the Magna. The tendency was to implant a numerically1392 The Journal of Thoracic and Cardiovascular Sursmaller (commercial size) Magna valve than the direct an-
nular measurement would suggest (mean,0.71 mm). The
operative surgeon documented the need to downsize the
implanted valve from the commercial size measured in 9
patients who received the Magna (9%) versus 6 patients
who received the Epic (6%) and 4 patients who received
the Mitroflow (4%; P ¼ .338). Patch enlargement of the
aortic annulus was performed in 5 patients who received
the Epic (5%), 4 patients who received the Magna
(4%), and 4 patients who received the Mitroflow (4%;
P ¼ .91). Isolated patch closure of the aortic root (without
annular enlargement) was required in 11 patients receiving
the Magna valve (11%) versus 7 patients receiving the
Epic valve (7%) and 8 patients receiving the Mitroflow
valve (8% P ¼ .58). Among patients with a small annulus
having a direct annular measurement of  21 mm, the uni-
versal size and implant size correlated best for the Mitro-
flow valve (P ¼ .045).DISCUSSION
This is the first prospective, randomized clinical trial of
patients with severe AS undergoing AVRwith the Epic, Ma-
gna, or Mitroflow valves. Small but consistent differences
were found. Valve performance was similar and statistically
indistinguishable among those patients with a small (21
mm) aortic annulus whereas the AVAi was slightly greater
in patients with a 23-mm annulus who received the Magna.
AVA and AVAi were comparable among all 3 valve types in
patients with a larger annular dimension (>23 mm); how-
ever, slightly lower transprosthetic gradients were notedgery c December 2012
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data were stratified either by commercially labeled valve
size or echocardiographically determined aortic annulus
size. The correlation between actual aortic annulus size
and implanted commercial valve size was best in the Epic
and Mitroflow groups.
The early postsurgical hemodynamic performance of the
3 valves studied was similar, in general, to previously re-
ported values from retrospective reviews.2,5,8,20 Although
the median implanted commercially labeled valve size
was no. 23 in the current study, we divided patients for
analysis into 3 equal groups to facilitate balanced
statistical comparison among physiologically similar
valve sizes. Mean transprosthetic gradients in the Epic
group ranged between 17.1 mm Hg (nos. 19 and 21) and
16.2 mm Hg (nos. 25 and 27) in our study, which were
slightly higher than those reported by Maitland
associates8 but similar to Ruzicka and co-authors,20 both
of whom detailed echocardiographic data accrued 6
months after implantation. AVA and AVAi were similar,
however, among these reports and the current study.8,20
Mean transprosthetic gradients in the Magna group
ranged between 16.6 mm Hg (nos. 19 and 21) and 11.9
mm Hg (nos. 25 and 27) in our series, which also were
slightly higher than those reported by Botzenhardt and
colleagues2 (at hospital dismissal), whereas AVA and
AVAi were again similar. Mitroflow valves showed similar
trends, with mean gradients between 16.7 mm Hg (nos. 19
and 21) and 14.5 mm Hg (nos. 25 and 27) in our study,
which were slightly higher than those reported by Jamie-
son and associates5 at a mean of 11 months after surgery,
whereas AVA and AVAi in our study were, conversely,
slightly greater. It is highly likely that heterogeneity in tim-
ing of hemodynamic assessments among our current and
other studies accounts for many of these differences. Ele-
vated circulating catecholamine levels along with in-
creased stroke volume and anemia early postoperatively
all play a role in altering flow-dependent parameters of
prosthetic valve function such as mean gradient and peak
velocity.13,21 Indeed, the postoperative increase in
cardiac index (compared with preoperative) was
significant overall in the current report (þ0.25  0.81,
P< .001). It is reassuring that the postoperative cardiac
index was similar among groups, thus facilitating
comparison of mean gradients among prostheses. It is
also notable that less flow-dependent measures of valve
performance such as AVA and AVAi in our study were sim-
ilar to prior published values in which echocardiographic
examinations were typically performed well beyond the
early postoperative period.
As others have shown,2,5,8,22 the comparison of
hemodynamic differences among bioprostheses after
correcting for actual annular size is important. It is
interesting that the differences in AVAi among devicesThe Journal of Thoracic and Carbased on labeled valve size, actual (universal) annulus
size, and echocardiography LVOT diameter were only
significant in the intermediate group (ie, those receiving
a no. 23 valve or having an annulus diameter of 23 mm).
Despite the fact that the maximal sewing cuff dimension
reported by Edwards for the Magna valve is intermediate
between the Epic andMitroflow (Table 4), slightly more pa-
tients receiving the Magna valve required prosthesis down-
sizing and patch closure of the aortic root by the operative
surgeon (P value not significant). This also supports our
finding that the Pearson correlation coefficients of the rela-
tionship between annulus and implant sizes were weakest in
the Magna group. Despite this, the Magna valve tended to
perform slightly better in those with a medium to large an-
nulus size. The Mitroflow had the smallest external sewing
cuff footprint and correlated better with actual annular size,
particularly in those with a small aortic annulus (<21 mm).
The prognostic impact of PPM has been debated widely.
Historic estimates suggest that the incidence of PPM in
stented aortic bioprostheses range from 20% to 70%.23,24
Varying degrees of PPM have been reported to influence
clinical outcome by some,25-30 whereas others remain
unconvinced.31-35 Differing methods used to calculate
PPM likely contribute to the heterogeneity of published
outcomes.36 A study by Connolly and colleagues37 from
Mayo Clinic identified small aortic valve prosthesis as an
independent predictor of poor early postsurgical survival
in those with severe preoperative LV dysfunction
(EF<35%).37 Specifically, Mohty and associates26 showed
that severe PPM predicted increased late mortality in those
<70 years old or with a body mass index >30 kg/m2,
whereas moderate PPM was a risk factor for death in
patients with an LVEF<50%. Urso and colleagues38 sum-
marized the recent literature by recommending that severe
mismatch may be deleterious in all patients whereas moder-
ate mismatch might be a problem only in those with LV dys-
function. Our study suggests that the risk of severe PPM in
patients receiving current-generation bioprosthetic aortic
valves is extremely low and that differences among the 3
valves tested here are small. One clinical interpretation of
the data is to suggest that patients with severe LV dysfunc-
tion and larger annular size may gain a small benefit from
the slightly lower gradient offered by the Magna valve;
however, randomized assessment of these 3 valves in pa-
tients with depressed preoperative LV function will be nec-
essary before such a conclusion can be drawn. When
considering less flow-dependent, and perhaps most objec-
tively assessed parameters (ie, AVA and AVAi), the actual
differences between the Magna and Mitroflow valves
were small.
As David and coworkers39 suggest in their recent re-
port, the debate regarding hemodynamic superiority and
late durability of porcine versus bovine pericardial bio-
prosthesis persists largely as a result of the fact thatdiovascular Surgery c Volume 144, Number 6 1393
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erogeneous patient populations. Similar to the current
study, Jamieson and colleagues40 compared the hemody-
namic performance of the Carpentier-Edwards (Edwards
LifeSciences) and Mosaic porcine aortic valves against
the Carpentier-Edwards bovine pericardial device, finding
that the mean gradient and AVAi were similar between the
2 valves, and thus concluded that there were no important
hemodynamic differences between porcine and pericardial
devices in the aortic position. In contrast, Wagner and as-
sociates24 examined the hemodynamic performance of 3
bovine pericardial aortic valves (Sorin Soprano, Carpent-
ier-Edwards Magna, and Carpentier-Edwards Perimount)
and 1 porcine valve (Medtronic Mosaic), concluding that
all 3 bovine pericardial valves showed lower transaortic
gradients and larger ‘‘effective orifice fraction.’’ A ran-
domized study41 of 152 patients from Mayo Clinic com-
pared the Mosaic porcine with the Carpentier-Edwards
Perimount bovine pericardial valves in the aortic position
and found that, although the mean gradient was higher and
the AVAi lower in the Mosaic group, both cohorts showed
similar regression of LV mass index at 1 year. Finally,
regarding late durability, David and coworkers39 studied
a large population of 1134 patients undergoing AVR
with the Hancock II porcine bioprosthesis and reported
that the freedom from structural valve deterioration at
20 years was 99.8% in patients>70 years. Even after ac-
counting for these reports, there remains a paucity of com-
parative effectiveness data detailing the late durability of
contemporary porcine versus bovine pericardial valves in
the current era. Longitudinal follow-up of our randomized
cohorts will thus hopefully facilitate further comment on
this issue in the future.
The notion of various devices performing differently
under specific physiologic circumstances has recently
been proposed by Gerosa and colleagues42 who detailed
hemodynamic comparisons using a pulse duplicator. Peri-
cardial valves (Soprano, Magna, and Mitroflow) showed
the lowest transvalvular gradients; the Mitroflow valve
performed best at 5 to 7 L/minute with the lowest gradient,
highest AVA, and lowest stroke work loss; whereas regur-
gitant volumes were highest for the Magna valve. A more
recent study by the same group43 reported that the Magna
and Mitroflow had significantly better hemodynamic per-
formance in comparison with porcine valves, particularly
with stroke volume-mediated increases in cardiac output.
They speculated further that the porcine valves might per-
form better in elderly patients in whom the increase in car-
diac output is heart rate mediated, presumably as a result
of the ‘‘increased pliability’’ of the valve at higher cycle
speeds. These findings may explain, in part, why the
Epic valve performed similarly in the current study to
pericardial valves in patients with a small aortic annulus
size.1394 The Journal of Thoracic and Cardiovascular SurLimitations
Patients randomized to each of the 3 implant groups had
similar preoperative characteristics, as typical of a random-
ized trial. Some of the measures of early hemodynamic per-
formance (mean gradient and peak aortic velocity) of the
devices studied in this report are undoubtedly influenced
by factors known to affect flow-dependent indices; how-
ever, we examined those parameters understood to be
more objective, such as AVA and AVAi. Continued
follow-up at the 1- and 5-year time points are essential to
more completely understanding the hemodynamic perfor-
mance, durability, and clinical outcomes (including
survival) of the randomized cohorts. Although echocardio-
grams were not performed in a core laboratory, cardiolo-
gists who contribute routinely to such studies analyzed
images using rigorousMayo Clinic protocols and standards.
Last, the oversight of one cardiologist (Dr Michelena) in
ensuring the homogeneous accrual and analysis of echocar-
diography data is reassuring.
CONCLUSIONS
This prospective, randomized comparison reveals that
there are small but consistent hemodynamic trends among
current third-generation porcine and pericardial aortic valve
prostheses. The 3 valves studied performed equally well in
patients with a small (21 mm) aortic annulus size.
The Magna valve had a slightly lower mean gradient in
those with a larger annulus size (>23 mm); however,
flow-independent parameters such as AVA and AVAi were
generally similar among groups. Longitudinal assessments
of these randomized cohorts will be essential to determine
late clinical implications of these early postoperative
findings.
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Dr Tirone E. David (Toronto, Ontario, Canada). Dr Suri and
his colleagues fromMayoClinic are to be commended for carrying
out this prospective, randomized trial on early hemodynamic per-
formance of 3 currently used bioprosthetic valves for AVR. Hemo-
dynamic assessment of bioprosthetic valves a few days after
implantation may not represent the final hemodynamic result of
the bioprosthesis at 6 months or 1 year, and I hope Dr Suri will
bring his patients back and tell us next year what happened to those
gradients and the aortic valve sizes. Our specialty certainly needs
more randomized controlled trials whenever possible, and choicediovascular Surgery c Volume 144, Number 6 1395
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colleagues’ randomized trial showed that the mean gradient across
the aortic valve was approximately 16 mmHg for Epic, 14 mmHg
for Magna, and 16 mm Hg for Mitroflow for the entire cohort of
patients, and these values were statistically different with a P value
of .01. Similarly, the aortic valve areas were 1.86 cm2 for Epic,
2.05 cm2 for Magna, and 1.88 cm2 for Mitroflow, and the differ-
ences were again statistically significant. And so were the indexed
orifice areas. My first question to you, Rakesh: Is there clinical rel-
evance in these differences? In other words, do you believe that
a mean gradient of 14 mm Hg or 16 mm Hg has any clinical
consequence?
Dr Suri. Thank you, Dr David, for those comments. We do not
currently believe that these small differences in transprosthetic
gradient have clinical relevance during the early postoperative pe-
riod. Cognizant of the fact that the perioperative changes in car-
diac output caused by catecholamine elevations, anemia, and
increased stroke volume early after surgery may temporarily ele-
vate the transprosthetic gradient, we further analyzed the flow-in-
dependent measures of valve performance such as uncorrected
AVA and AVAi. These comparisons also showed only very small
differences among devices. It is interesting to note that there
were slight variances in the outcome of the comparative analyses
depending on whether data were stratified by implant size or ac-
tual annular size. Our European colleagues have written about
these varying methods of analysis, stressing the importance of nor-
malizing hemodynamic data by actual annular size to account for
differences in commercial valve labeling. What is striking is that
when we controlled for discrepancies in commercial size labeling,
many of the differences among devices disappeared and the per-
formance of the 3 valves over a range of directly measured univer-
sal annulus sizes was quite similar. Finally, our randomized
cohorts are scheduled for clinical and echocardiographic follow-
ups at 1 year and 5 years. We are currently seeing patients for their
1-year visit. We look forward to presenting these data in the
future.
Dr David. Patient–prosthesis mismatch is really what we
should try to avoid during AVR, particularly in patients who are
physically very active or have impaired LV systolic function.
Your trial showed that the average aortic valve index was around
1 cm2/m2 in all 3 groups of patients, and I commend you again
for trying to implant the largest possible valve to avoid patient–
prosthesis mismatch. However, your surgeons had to patch enlarge
the annulus in approximately 10% of your patients. Because the
randomization was done after the patch enlargement, patch en-
largement did not affect the outcomes, but it did bias the result
on the hemodynamic performance of the valves. My next question
to you is related to the fact that, although Magna showed the best
hemodynamic performance, it also had the highest incidence of
annular enlargement and also the highest incidence of mismatch.
Although the differences were not statistically significant, they
are, however, significant for the average surgeon who doesn’t do
this operation every day.
Dr Suri. Those are important considerations. To address your
first point, when designing the trial protocol, we thought about
surgical strategy in the following way. Assuming hemodynamic
equipoise among devices, we wanted to understand the implica-
tions of placing each of the 3 valves in a given annular orifice.1396 The Journal of Thoracic and Cardiovascular SurWe thus left it to the surgeon to perform an a priori assessment
of whether aortic annular enlargement would first be required
based on the estimated physiologic needs of the patient. What
is reassuring is that all valves performed similarly well using
this strategy, and the frequency of annular enlargement was com-
parable among groups. The specific question regarding who en-
larges the aortic annulus is more complicated, and this study
does not address that issue. These data indicate, however, that
regardless of the valve type placed in a small aortic annulus,
flow-dependant and -independent performance of the devices
were indistinguishable statistically. Last, these data could also
be interpreted to imply that in those with LV dysfunction, or
who require maximization of postoperative AVA, annular en-
largement is required. In other words, merely selecting a different
prosthesis for a given annular dimension will not necessarily pro-
vide a significant increase in postoperative indexed orifice area.
An interesting point to note in the data provided by the 3 compa-
nies themselves, which detail differences in dimensions of the 3
devices, are actual external valve size measurements. The Mitro-
flow valve has the smallest external diameter footprint, yet the
valve performed very similarly to those with larger internal and
external diameters. Finally, I will try to address your point on
patch closure of the aortic root. To clarify, 4% of patients under-
went patch enlargement of the aortic annulus and 10% had patch
closure of the aortic root only. Despite the fact that the Magna
valve is intermediate in external diameter and stent height be-
tween the 2 groups, the question is why surgeons slightly more
frequently used a bovine pericardial patch to close the aortic
root. Many of you will have your own suspicions regarding differ-
ences in stent characteristics; however, this study was not de-
signed to draw definitive conclusions on that topic.
Dr David. Finally, if the hemodynamic performance of differ-
ent porcine and pericardial valves is similar, surgeons should
have to consider the durability of the bioprosthetic valve when
matching the patient to the type of valve. One should not implant
a valve only because it has excellent hemodynamic performance. I
would like to thank The American Association for Thoracic Sur-
gery for the privilege of discussing this paper.
Dr Suri. Thank you again, Dr David. That is a very important
point. Dr David has recently published a seminal paper on long-
term durability of biologic aortic valve prostheses and I encourage
those of you who haven’t read it to do so. The current study, Dr Da-
vid, reflects the first step in our planned long-term follow-up of
these patients. We hope to comment both on mid- and long-term
durability of these devices in the future.
Dr Lawrence H. Cohn (Boston, Mass). I have a question about
the patch enlargement. I have always been fascinated with this.
The mean age of your group was 76 years of age and yet you patch
enlarged 10%, or 30 of the patients. Could you give us a feel for
what kind of patient you are enlarging at this age group? A lot
of these patients in my practice are elderly women—80 years
old—and all they want to do is walk down the mall with their
grandchildren, so we put in 19-mm and 21-mm valves quite fre-
quently. I am would be curious as to what kind of patients were
patched in this age group.
Dr Suri. That is a very interesting question, Dr Cohn. As you
are aware in your own practice, we all do things slightly differ-
ently and thus have varying predispositions toward enlargementgery c December 2012
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patient–prosthesis mismatch; some use charts and other clinical
judgment based on accrued surgical experience. Further, there is
general agreement that severe mismatch is particularly problem-
atic in those who are active or who have preoperative LV
dysfunction, and thus at Mayo Clinic we would be particularly
aggressive in enlarging the annulus of these patient subsets, as
we did in 4% of the current study population. We are not sug-
gesting that cardiac surgeons should be enlarging the annulus
of all patients, particularly as you point out, in those who are
frail and merely require amelioration of severe calcific AS to re-
store their quality of life with limited requirement for physical
activity.
Dr Rohit Shahani (Poughkeepsie, NY). Thank you for a nice
paper. When we talk about small sizes in the aorta, could you
tell us in absolute numbers how many of the valves you put in
were 19?
Dr Suri. Fourteen valves of size 19 were implanted overall: 3
Epic, 6 Magna, and 5 Mitroflow.
Dr Robert A. Dion (Genk, Belgium). Don’t you think that,
based on your findings, one still can make a decision about using
a very small size? I have the impression that 1 of the 3 is doing bet-
ter in gradients and in areas. Also, if one is confronted with a very
small annulus and is being forced to insert<size 21, what would
you do?Would you carry on enlarging the aortic root or would you
go, for instance—what I am doing—for a full-root supra-annular
stentless valve? Thank you.
Dr Suri. Thank you, Dr Dion. Those are good questions. The
first point I will address is your last question, and I concur with
the perspective of Dr Cohn on this; severe aortic stenosis patients
with a normal ventriclewho are small, elderly, frail, and have a nor-
mal ventricle can do very well with a no. 19 valve in the absence of
severe mismatch. Notably, our data suggest that all valves studied
in this randomized series performed equally well, with a low fre-
quency of PPM in patients with a small aoric annulus. As is the
case with most surgical decisions in our specialty, a thoughtful
analysis of advantages and disadvantages as related to the specific
clinical scenario in each patient is warranted. Additionally, we do
not typically implant stentless valves or routinely enlarge the aor-
tic annulus in small, frail, elderly patients unless there is predicted
physiologic need based on individual clinical circumstances. The
other question, as I understand it, is regarding the small hemody-
namic differences noted between the combined commercial sizes
nos. 19 and 21 groups. As I mentioned, longitudinal follow-up
will be essential to track these 3 well-matched randomized subsets
over time. Although one may speculate regarding potential late
outcomes, we cannot currently conclude that there are clinicallyThe Journal of Thoracic and Carmeaningful hemodynamic differences among any of the random-
ized valve groups during the early postoperative period.
Dr Guo-Wei He (Tianjin, China). I feel this is a very important
study from the Mayo Clinic. Now, our practice pattern in China is
different from your practice in the Mayo Clinic. In my own prac-
tice, up to 50% of the patients are still the result of rheumatic
heart disease; another 50% are attributed to another etiology
such as degeneration or infection. I have a question related to pa-
tients between the ages of 60 years and 65 years. In this situation,
we may put either a bioprosthesis or a mechanical valve in. I
would like to know, in the Mayo Clinic experience, as far as
the hemodynamic effect is concerned, in this age group, which
valve prosthesis would you use? A bioprosthesis or a mechanical
valve?
Dr Suri. This is a very interesting question. There are 2 factors
we discuss we consider when helping patients decide between
mechanical versus biological valve substitutes in the so-called
gray zone. The first, as you said, is hemodynamic performance.
In the current era with novel, third-generation biologic devices,
the hemodynamic differences between mechanical and biologic
devices are not large, and thus this seldom is the most influential
factor in determining prosthesis choice. The second point is an
important and less well understood concept—the late potential
survival difference between valve types. There is a growing
body of evidence to suggest that there may be a long-term survival
advantage associated with implantation of a mechanical versus
a biologic aortic valve in risk-matched middle-aged patients. Of
course, the opposing argument would be that the quality-of-life
implications of oral anticoagulants are more influential on pros-
thesis choice. However, that debate is beyond the scope of the dis-
cussion today. We currently have a manuscript submitted that
addresses the late prognostic implications of mechanical versus
biologic aortic valve replacement and we hopefully will have
more to share on the topic in the near future. Ultimately, patients
at Mayo Clinic undergoing preoperative assessment for valve re-
placement are thoroughly informed of indications, risks, benefits,
and alternatives before selecting an appropriate prosthetic valve
substitute.
Dr Joseph Ladowski (Ft. Wayne, Ind). Dr Suri, not an elegant
question, but a practical one. If you yourself needed one of these
valves tomorrow, which one do you want?
Dr Suri. For the sake of maintaining equipoise as the principal
investigator of this study, and as the data have confirmed is war-
ranted at the current time in light of small differences between
the valves studied in this trial, I am going to politely defer that
question. I thank The American Association for Thoracic Surgery
for the opportunity to present our data today.diovascular Surgery c Volume 144, Number 6 1397
APPENDIX 1. Dismissal echocardiogram data comparison stratified by implant size
Implant size Dismissal echocardiogram Epic (n ¼ 29) Magna (n ¼ 35) Mitroflow (n ¼ 36) P value
Nos. 19 and 21 (n ¼ 100) n ¼ 29 n ¼ 35 n ¼ 36
Mean gradient, mm Hg 17.11  6.29 (15.50) 16.62  6.35 (16.00) 16.66  6.12 (16.00) .945
Aortic valve area, cm2 1.55  0.29 (1.56) 1.61  0.34 (1.66) 1.59  0.40 (1.59) .799
Aortic valve area index, cm2/m2 0.86  0.18 (0.86) 0.92  0.21 (0.92) 0.92  0.27 (0.89) .581
No. 23 (n ¼ 94) n ¼ 33 n ¼ 33 n ¼ 30
Mean gradient, mm Hg 16.26  5.57 (18.00) 14.16  4.88 (14.00) 17.97  6.18 (18.00) .032*
Aortic valve area, cm2 1.79  0.37 (1.79) 2.02  0.32 (1.96) 1.80  0.39 (1.81) .025y
Aortic valve area index, cm2/m2 0.91  0.23 (0.87) 1.04  0.21 (0.96) 0.90  0.20 (0.90) .028z
Nos. 25 and 27 (n ¼ 106) n ¼ 37 n ¼ 34 n ¼ 35
Mean gradient, mm Hg 16.24  7.29 (16.00) 11.91  3.98 (11.00) 14.54  5.67 (13.00) .009x
Aortic valve area, cm2 2.17  0.47 (2.18) 2.50  0.49 (2.45) 2.25  0.52 (2.12) .019jj
Aortic valve area index, cm2/m2 1.05  0.28 (1.02) 1.18  0.26 (1.09) 1.08  0.28 (1.05) .158
Echocardiogram variables are summarized as mean  (median). *Epic vs Magna, P ¼ .290; Epic vs Mitroflow, P ¼ .461; Magna vs Mitroflow, P ¼ .024. yEpic vs Magna,
P¼ .042; Epic vs Mitroflow, P¼ .989; Magna vs Mitroflow, P ¼ .057. zEpic vs Magna, P¼ .068; Epic vs Mitroflow, P¼ .986; Magna vs Mitroflow, P¼ .044. xEpic vs Magna,
P ¼ .007; Epic vs Mitroflow, P ¼ .437; Magna vs Mitroflow, P ¼ .154. jjEpic vs Magna, P ¼ .019; Epic vs Mitroflow, P ¼ .770; Magna vs Mitroflow, P ¼ .102.
APPENDIX 2. Dismissal echocardiogram data comparison stratified by universal size
Universal size, mm Dismissal echocardiogram Epic Magna Mitroflow P value
<23 mm (n ¼ 77) n ¼ 23 n ¼ 24 n ¼ 30
Mean gradient, mm Hg 16.50  6.01 (14.50) 17.13  6.74 (16.00) 16.41  6.72 (16.00) .917
Aortic valve area, cm2 1.55  0.32 (1.57) 1.62  0.39 (1.67) 1.68  0.43 (1.63) .547
Aortic valve area index, cm2/m2 0.86  0.19 (0.86) 0.93  0.25 (0.92) 0.96  0.28 (0.94) .366
23 mm (n ¼ 95) n ¼ 32 n ¼ 28 n ¼ 35
Mean gradient, mm Hg 16.87  6.10 (18.00) 14.00  4.15 (14.00) 16.74  5.90 (16.00) .084
Aortic valve area, cm2 1.70  0.34 (1.66) 1.91  0.33 (1.87) 1.78  0.47 (1.65) .138
Aortic valve area index, cm2/m2 0.88  0.20 (0.85) 1.02  0.18 (0.97) 0.91  0.24 (0.87) .040*
>23 mm (n ¼ 128) n ¼ 44 n ¼ 48 n ¼ 36
Mean gradient, mm Hg 16.25  6.95 (16.00) 12.98  5.07 (12.00) 15.81  5.86 (14.50) .021y
Aortic valve area, cm2 2.12  0.47 (2.18) 2.34  0.54 (2.17) 2.14  0.53 (2.05) .103
Aortic valve area index, cm2/m2 1.04  0.28 (1.00) 1.12  0.27 (1.07) 1.03  0.27 (1.01) .275
Echocardiogram variables are summarized as mean  standard deviation (median). *Epic vs Magna, P ¼ .045; Epic vs Mitroflow, P ¼ .886; Magna vs Mitroflow, P ¼ .106.
yEpic vs Magna, P ¼ .027; Epic vs Mitroflow, P ¼ .942; Magna vs Mitroflow, P ¼ .086.
APPENDIX 3. Dismissal echocardiogram data comparison stratified by LVOT size
LVOT size Dismissal echocardiogram Epic Magna Mitroflow P value
21 (n ¼ 85) n ¼ 23 n ¼ 30 n ¼ 32
Mean gradient, mm Hg 18.09  8.87 (15.00) 15.62  6.66 (14.00) 15.32  5.96 (15.00) .332
Aortic valve area, cm2 1.59  0.27 (1.58) 1.69  0.37 (1.76) 1.84  0.54 (1.67) .116
Aortic valve area index, cm2/m2 0.88  0.17 (0.87) 0.94  0.20 (0.93) 1.02  0.29 (1.01) .099
22-23 (n ¼ 29) n ¼ 44 n ¼ 41 n ¼ 44
Mean gradient, mm Hg 16.43  5.38 (16.50) 14.88  5.56 (16.00) 17.09  6.43 (17.50) .205
Aortic valve area, cm2 1.88  0.47 (1.86) 2.06  0.46 (2.03) 1.78  0.47 (1.63) .029*
Aortic valve area index, cm2/m2 0.96  0.27 (0.91) 1.06  0.26 (0.98) 0.90  0.24 (0.88) .017y
>23 (n ¼ 84) n ¼ 31 n ¼ 28 n ¼ 25
Mean gradient, mm Hg 15.48  5.68 (16.00) 11.82  2.89 (11.00) 16.16  5.66 (16.00) .003z
Aortic valve area, cm2 2.03  0.50 (1.96) 2.40  0.55 (2.30) 2.10  0.52 (2.02) .027x
Aortic valve area index, cm2/m2 0.99  0.27 (0.93) 1.13  0.26 (1.07) 1.02  0.27 (1.01) .161
Echocardiogram variables are summarized as mean standard deviation (median). LVOT, Left ventricular outflow tract. *Epic vsMagna, P¼ .222; Epic vsMitroflow, P¼ .571;
Magna vs Mitroflow, P¼ .022. yEpic vs Magna, P¼ .163; Epic vs Mitroflow, P¼ .558; Magna vs Mitroflow, P¼ .013. zEpic vs Magna, P¼ .015; Epic vs Mitroflow, P¼ .866;
Magna vs Mitroflow, P ¼ .006. xEpic vs Magna, P ¼ .029; Epic vs Mitroflow, P ¼ .863; Magna vs Mitroflow, P ¼ .110.
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